SHCDN006
SHCDNi006-A
General
Cell Line |
|
| hPSCreg name | SHCDNi006-A |
| Cite as: | SHCDNi006-A (RRID:CVCL_B5RS) |
| Alternative name(s) |
SHCDN006
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
ZJSHi001-A (ZJSHi-KCNB1) Donor's gene variants: KCNB1 Donor diseases: developmental and epileptic encephalopathy, 26 PUFHi004-A (TMEM163 c.227T>C p.(Leu76Pro) iPSC) Donor's gene variants: TMEM 163 Donor diseases: Leukodystrophy PFIZi023-A (B217c8) Donor's gene variants: GPR56, GPR56 Donor diseases: Bilateral Frontoparietal Polymicrogyria |
| Last update | 6th May 2022 |
| User feedback | |
Provider |
|
| Generator |
Shanghai Children's Hospital (SHCDN)
Contact:
Department of Neurology (BCHNEU) |
| Owner | Department of Neurology (BCHNEU) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA14207087 |
| Cellosaurus | CVCL_B5RS |
| Wikidata | Q112041713 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
Additional restrictions:
none |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | NONE |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
The karyotype of SHCDNi006-A iPSCs was examined by Giemsa-banding to verify genetic stability, and showed that 23 pairs of chromosomes with normal structure
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA14207088 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Committee of Shanghai Children's Hospital |
| Approval number | REK 2017R021-F01 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Committee of Shanghai Children's Hospital |
| Approval number | REK 2017R021-F01 |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Source cell line vendor | Shanghai Children's Hospital |
| Passage number reprogrammed | 10 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
Protein
|
Other |
|
| Selection criteria for clones | cells are small and present a compact group |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | ACCUTASE |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Present | Absent |
| mCpG | ||
| OCT4 | X |
Report
Morphology pictures
明场图-N140007-王梓怡-1.tif
morphology
To verify the tri-lineage differentiation potential of the cells, the markers SOX1 (for ectoderm), BMP4 (for mesoderm) and GATA4 (for endoderm) were used clarify differentiation capacity by Real-time qPCR experiment. The relative fold changes of gene expression between differentiated cells and iPSCs. (Ectoderm: SOX1; Mesoderm: BMP4; Endoderm: GATA4), n=3.
Method documentation
Differentiation Potency
Microbiology / Virus Screening |
|
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
The karyotype of SHCDNi006-A iPSCs was examined by Giemsa-banding to verify genetic stability, and showed that 23 pairs of chromosomes with normal structure
Passage number: 10
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Login to share your feedback, experiences or results with the research community.